NYSE · COR
Healthcare · Medical - Distribution
$322.03
Up+$0.80 (+0.25%)
Updated Aug 30, 2026, 8:32 AM
SID Score
5.4/10
Composite research score
Smart Money
55/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
COR closed at $322.03 after 20 trading sessions, up 4.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $322.30 | $323.74 | $320.39 | $322.03 | 628.86K |
| Aug 27, 2026 | $324.35 | $324.68 | $320.465 | $321.23 | 1.07M |
| Aug 26, 2026 | $328.39 | $330.995 | $326.30 | $327.79 | 841.57K |
| Aug 25, 2026 | $322.68 | $328.51 | $321.43 | $328.06 | 1.11M |
| Aug 24, 2026 | $317.76 | $324.58 | $317.65 | $323.77 | 760.4K |
| Aug 21, 2026 | $314.74 | $320.2137 | $313.13 | $318.04 | 905.4K |
| Aug 20, 2026 | $314.77 | $318.23 | $312.605 | $314.69 | 1.18M |
| Aug 19, 2026 | $314.03 | $322.50 | $312.02 | $317.10 | 1.18M |
| Aug 18, 2026 | $315.99 | $320.00 | $313.92 | $316.13 | 1.03M |
| Aug 17, 2026 | $312.00 | $318.23 | $311.43 | $312.52 | 992.05K |
| Aug 14, 2026 | $304.78 | $314.31 | $302.01 | $313.82 | 1.52M |
| Aug 13, 2026 | $312.10 | $315.301 | $309.71 | $310.01 | 1.54M |
| Aug 12, 2026 | $319.59 | $323.59 | $312.67 | $314.17 | 2.61M |
| Aug 11, 2026 | $325.60 | $333.95 | $324.30 | $333.87 | 1.37M |
| Aug 10, 2026 | $321.07 | $325.69 | $319.92 | $325.00 | 1.55M |
| Aug 7, 2026 | $324.00 | $328.99 | $319.46 | $320.46 | 1.56M |
| Aug 6, 2026 | $321.88 | $326.79 | $312.28 | $325.01 | 2.93M |
| Aug 5, 2026 | $316.00 | $326.99 | $311.00 | $317.22 | 2.29M |
| Aug 4, 2026 | $305.95 | $308.33 | $301.23 | $306.28 | 2.45M |
| Aug 3, 2026 | $313.78 | $313.87 | $307.76 | $308.37 | 1.6M |
The latest Smart Investors Daily articles mentioning COR.
COR research
Company profile and research snapshot.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | RBC Capital | Sector Perform | — |
| Aug 11, 2026 | Wells Fargo | Overweight | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | Morgan Stanley | Overweight | — |
| Aug 6, 2026 | Evercore ISI Group | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 26, 2026
It was reported on August 25, that Elizabeth S Campbell, Executive Vice President at Cencora (NYSE:COR) executed a significant insider sell, according to an SEC filing. What Happened: After conducting a thorough
Fintel · Aug 20, 2026
Benzinga · Aug 19, 2026
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.61% on an annualized basis producing an average annual return of 19.99%. Currently, Cencora has a market capitalization of $60.51 billion.
Benzinga · Aug 19, 2026
RBC Capital analyst Ryan Halsted initiates coverage on Cencora (NYSE:COR) with a Sector Perform rating and announces Price Target of $330.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COR.
